載入...
NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
The heterogeneity of ALK tyrosine-kinase inhibitor (TKI) responses poses a puzzling question to clinicians. Different variants of ALK rearrangements might be one of the mechanisms explaining this phenomenon. Therefore, identifying specific fusion forms is crucial to clinical practice. This case repo...
Na minha lista:
| 發表在: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6369846/ https://ncbi.nlm.nih.gov/pubmed/30799936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S192367 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|